Download PDF
Pharmacopsychiatry 2001; 34(4): 128-131
DOI: 10.1055/s-2001-15871
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Survey on the Usefulness of Trazodone in Patients with PTSD with Insomnia or Nightmares

M. D. Warner1 , M. R. Dorn2 , C. A. Peabody3
  • 1University of Michigan Medical Center, Michigan, USA
  • 2Stanford University Medical Center, Palo Alto, California, USA
  • 2University of Michigan and Quality Management Officer Veterans Affairs Network Office 11, Ann Arbor, Michigan, USA
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Background: Trazodone is commonly used in the treatment of insonmia and nightmares in patients with PTSD. There is little evidence in the literature for this practice. Method: Seventy-four patients from the Palo Alto Veterans Affairs Health Care System in California who were admitted to a specialized 8 week inpatient treatment program for PTSD were surveyed regarding their use of trazodone in the treatment of insomnia or nightmares. Patients were asked to complete a questionnaire regarding trazodone's effectiveness, side effects, and optimal doses. Results: Of 74 patients surveyed, 60 patients were able to maintain an effective dose of trazodone. The other 14 patients were unable to tolerate the medication. Seventy-two percent of the 60 patients assessed found trazodone helpful in decreasing nightmares, from an average of 3.3 to 1.3 nights per week (p < .005). Ninety-two percent found it helped with sleep onset, and 78 % reported improvement with sleep maintenance. There was a significant correlation between the effectiveness in decreasing nightmares and improving sleep (r = .57, p < .005). The effective dose range of trazodone for 70 % of patients was 50 to 200 mg nightly. Of the 74 patients surveyed, 9 (12 %) reported priapism. Conclusion: Trazodone appears effective for the treatment of insomnia and nightmares associated with chronic PTSD. However, controlled trials are needed before any definite conclusions can be drawn. The higher than expected occurrence of priapism warrants clinicians asking directly about this side effect.

References

  • 1 Ahmad S. Paroxetine-induced priapism.  Arch Intern Med. 1995;  155 645
    PubMedGoogle Scholar
  • 2 Benkelfat C, Jay C, Renardet M. Use of interactive computer technology in open label clinical trials.  Neuropsychobiology. 1986;  15 (suppl 1) 48-56
    PubMedGoogle Scholar
  • 3 Brown P J, Wolfe J. Substance abuse and post traumatic stress disorder comorbidity.  Drug Alcohol Depend. 1994;  35 51-59
    PubMedGoogle Scholar
  • 4 Chilcoat H D, Breslan N. Post traumatic stress disorder and drug disorders.  Arch Gen Psychiatry. 1998;  55 913-917
    PubMedGoogle Scholar
  • 5 Deirmenjian J M, Erhart S M, Wirshing D A, Spellberg B J, Wirshing W C. Olanzapine-induced reversible priapism: a case report.  J Clin Psychopharmacol. 1998;  18 (4) 351-352
    CrossrefPubMedGoogle Scholar
  • 6 Emes C E, Millson R C. Risperidone-induced priapism.  Canadian Journal of Psychiatry. 1994;  39 (4) 315-316
    PubMedGoogle Scholar
  • 7 Fabre L F. United States experience and perspectives with trazodone.  Clin Neuropharmacol. 1989;  12 (suppl) 511-517
    PubMedGoogle Scholar
  • 8 Feighner J P, Boyer W F. Overview of USA controlled trials of trazodone in clinical depression.  Psychopharmacology. 1988;  95 550-553
    PubMedGoogle Scholar
  • 9 Fishbain D A. Priapism resulting from fluphenazine hydrochloride treatment reversed by diphenhydramine.  Ann Emerg Med. 1985;  14 (6) 600-602
    PubMedGoogle Scholar
  • 10 Hargrave R. Serotonergic agents in the management of dementia and post traumatic stress disorder.  Psychosomatics. 1993;  34 461-462
    PubMedGoogle Scholar
  • 11 Haria M, Fitton A, McTavish D. Trazodone: A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.  Drugs and Aging. 1994;  4 (4) 331-355
    PubMedGoogle Scholar
  • 12 Hertzberg M A, Feldmann M E, Beckham J C, Davidson J R T. Trial of trazodone for post traumatic stress disorder using a multiple baseline group design.  J Clin Psychopharmacol. 1996;  16 294-298
    CrossrefPubMedGoogle Scholar
  • 13 Jacobsen F M. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study.  J Clin Psychiatry. 1990;  51 298-302
    PubMedGoogle Scholar
  • 14 Kessler R C, Sonnega A, Bromet E, Hughes M, Nelson C B. Post traumatic stress disorder in the National Comorbidity Survey.  Arch General Psychiatry. 1995;  52 1048-1060
    Google Scholar
  • 15 Kogeorgos J, de Alwis C. Priapism and psychtropic medication.  Br J Psychiatry. 1986;  149 241-243
    PubMedGoogle Scholar
  • 16 Kulmala R, Lehtonen T, Nieminen P, Tammela T. Aetiology of priapism in 207 Patients.  Eur Urol. 1995;  28 241-245
    PubMedGoogle Scholar
  • 17 Levenson J L. Priapism associated with buproprion treatment.  Am J Psychiatry. 1995;  152 (5) 813
    PubMedGoogle Scholar
  • 18 McFall M E, Mackay P W, Donovan D M. Combat-related post traumatic stress disorder and the severity of substance abuse in Vietnam veterans.  J Stud Alcohol. 1992;  53 357-363
    PubMedGoogle Scholar
  • 19 Mellman T A, Kulick-Bell R, Ashlock L E, Nolan B. Sleep events among veterans with combat related post traumatic stress disorder.  Am J Psychiatry. 1995;  1 110-115
    PubMedGoogle Scholar
  • 20 Mendelson W B, Franko T. Priapism with sertraline and lithium.  J Clin Psychopharmacol. 1994;  14 (6) 434-435
    PubMedGoogle Scholar
  • 21 Menza M A. Withdrawal syndrome in a depressed patient treated with trazodone.  Am J Psychiatry. 1986;  143 1195
    PubMedGoogle Scholar
  • 22 Metz A, Shader R I. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine.  Int Clin Psychopharmacol. 1990;  5 191-194
    PubMedGoogle Scholar
  • 23 Murray M J, Hoobermann D. Fluoxetine and prolonged erection.  Am J Psychiatry. 1993;  150 (1) 167-168
    PubMedGoogle Scholar
  • 24 Neylan T C, Marmar C R, Metzler T J, Weiss D S, Zatzick D F, Dehecchi K L, Wu R M, Schoenfeld F B. Sleep disturbances in the Vietnam generation: Findings from a nationally representative sample of male Vietnam veterans.  Am J Psychiatry. 1998;  155 929-933
    PubMedGoogle Scholar
  • 25 Nierenberg A A, Cole J O, Glass L. Possible trazodone potentation of fluoxetine: a case series.  J Clin Psychiatry. 1992;  53 83-85
    PubMedGoogle Scholar
  • 26 Nierenberg A A, Keck P E . Management of monoamine oxidase inhibitor-associated insomnia with trazodone.  J Clin Psychopharmacol. 1989;  9 42-45
    PubMedGoogle Scholar
  • 27 Nierenberg A A, Adler L A, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia.  Am J Psychiatry. 1994;  151 1069-1072
    PubMedGoogle Scholar
  • 28 Rand E H. Priapism in a patient taking sertraline.  J Clin Psychiatry. 1998;  59 (10) 538
    PubMedGoogle Scholar
  • 29 Rascertti K. Drug utilization review of concomittant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications.  Clinical Therapeutics. 1995;  17 786-790
    CrossrefPubMedGoogle Scholar
  • 30 Schatzberg A. Trazodone: a 5-year review of antidepressant efficacy.  Psychopathology. 1987;  20 (suppl 1) 48-56
    PubMedGoogle Scholar
  • 31 Yeragani V K, Gershon S. Priapism related to phenelzine therapy.  NEJM. 1987;  327 117-118
    PubMedGoogle Scholar
  • 32 Zimmer B, Doly F, Benjamin L. More on combination antidepressant therapy.  Arch Gen Psychiatry. 1984;  41 527-528
    PubMedGoogle Scholar

Cecilia PeabodyMD 

VISN Network Office 11

PO Box 13 40 02

Ann Arbor, MI 48113

USA

Phone: 001-734-930-5608

Fax: 001-734-930-5932

Email: penny.peabody@med.va.gov

      >